Search Results - "SHULMAN, L. N"

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511) by Freedman, Rachel A., Seisler, D. K., Foster, J. C., Sloan, J. A., Lafky, J. M., Kimmick, G. G., Hurria, A., Cohen, H. J., Winer, E. P., Hudis, C. A., Partridge, A. H., Carey, L. A., Jatoi, A., Klepin, H. D., Citron, M., Berry, D. A., Shulman, L. N., Buzdar, A. U., Suman, V. J., Muss, H. B.

“…Purpose We examined acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) events among 9679 women treated for breast cancer on four adjuvant Alliance…”
Get full text

Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance) by Chhibber, A, Mefford, J, Stahl, E A, Pendergrass, S A, Baldwin, R M, Owzar, K, Li, M, Winer, E P, Hudis, C A, Zembutsu, H, Kubo, M, Nakamura, Y, McLeod, H L, Ratain, M J, Shulman, L N, Ritchie, M D, Plenge, R M, Witte, J S, Kroetz, D L

“…Peripheral neuropathy is a common dose-limiting toxicity for patients treated with paclitaxel. For most individuals, there are no known risk factors that…”
Get full text

Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene–Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian Cancer by Vasey, P. A.

Get full text

Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer by BURSTEIN, H. J, MANOLA, J, WINER, E. P, YOUNGER, J, PARKER, L. M, BUNNELL, C. A, SCHEIB, R, MATULONIS, U. A, GARBER, J. E, CLARKE, K. D, SHULMAN, L. N

“…To evaluate the safety and efficacy of weekly docetaxel in women with metastatic breast cancer. Twenty-nine women were enrolled onto a study of weekly…”
Get full text

Second Malignancies After Treatment for Laparotomy Staged IA-IIIB Hodgkin's Disease: Long-Term Analysis of Risk Factors and Outcome by Mauch, Peter M., Kalish, Leslie A., Marcus, Karen C., Coleman, C.Norman, Shulman, Lawrence N., Krill, Elisa, Come, Steven, Silver, Barbara, Canellos, George P., Tarbell, Nancy J.

“…The survival of patients with Hodgkin's disease has dramatically improved over the past 30 years because of advances in treatment. However, concern for the…”
Get full text

The Sequencing of Chemotherapy and Radiation Therapy after Conservative Surgery for Early-Stage Breast Cancer by Recht, Abram, Come, Steven E, Henderson, I. Craig, Gelman, Rebecca S, Silver, Barbara, Hayes, Daniel F, Shulman, Lawrence N, Harris, Jay R

“…The temporal order in which patients with early-stage invasive breast cancer receive chemotherapy and radiation therapy after breast-conserving surgery may…”
Get full text

High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study by Shipp, M A, Neuberg, D, Janicek, M, Canellos, G P, Shulman, L N

“…To purpose of this study was to develop a more effective approach to the treatment of patients with poor-prognosis aggressive non-Hodgkin's lymphoma (NHL)…”
Get more information

Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy by Janicek, M, Kaplan, W, Neuberg, D, Canellos, G P, Shulman, L N, Shipp, M A

“…This prospective study assessed the predictive value of early restaging gallium (Ga) and computed tomographic (CT) scans in poor-prognosis patients with…”
Get more information

Primary systemic treatment of advanced Hodgkin’s disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up by Canellos, G. P., Gollub, J., Neuberg, D., Mauch, P., Shulman, L. N.

“…Background: The most commonly used regimen for the treatment of advanced Hodgkin’s disease (HD) is ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine)…”
Get full text

Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma by Abner, Anthony L., Collins, Laura, Peiro, Gloria, Recht, Abram, Come, Steven, Shulman, Lawrence N., Silver, Barbara, Nixon, Asa, Harris, Jay R., Schnitt, Stuart J., Connolly, James L.

“…BACKGROUND The prognosis of patients with T1 breast carcinoma remains controversial. Some studies have shown a low risk of lymph node metastasis and distant…”
Get full text

Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease by Bodis, S, Kraus, M D, Pinkus, G, Silver, B, Kadin, M E, Canellos, G P, Shulman, L N, Tarbell, N J, Mauch, P M

“…The patterns of presentation, histologic pattern (nodular or diffuse), treatment, and long-term outcome were studied in patients with lymphocyte-predominant…”
Get more information

Global oncology fellowship electives: The impact on cancer care and international collaborations by Butonzi, John, Shyirambere, Cyprien, Lansigan, Frederick, Rusangwa, Christian, Davis, Thomas H., Hill, Addie, Rose, Kelly, DeBoer, Rebecca Jane, Ruhangaza, Deogratias, Chamberlin, Mary D.

“…Abstract only…”
Get full text

Phase II study of topotecan in metastatic non-small-cell lung cancer by Lynch, Jr, T J, Kalish, L, Strauss, G, Elias, A, Skarin, A, Shulman, L N, Posner, M, Frei, 3rd, E

“…Topotecan is an inhibitor of topoisomerase I that has shown preclinical activity against non-small-cell lung cancer (NSCLC). This phase II study was designed…”
Get more information

Skin recurrences after breast-conserving therapy for early-stage breast cancer by Gage, I, Schnitt, S J, Recht, A, Abner, A, Come, S, Shulman, L N, Monson, J M, Silver, B, Harris, J R, Connolly, J L

“…To assess the frequency and prognosis of skin recurrences after breast-conserving therapy (BCT) compared with other breast recurrences. From 1968 to 1986,…”
Get more information

Primary mediastinal large-B-cell lymphoma: radiologic findings at presentation by Shaffer, K, Smith, D, Kirn, D, Kaplan, W, Canellos, G, Mauch, P, Shulman, LN

“…Primary mediastinal large-B-cell lymphoma was recently reclassified as a distinct clinical entity. We wished to review the imaging findings for this disease…”
Get full text

The biology of alkylating-agent cellular injury by Shulman, L N

“…Alkylating agents, such as nitrogen mustard, cyclophosphamide, and the nitrosoureas, have been used to treat many malignancies for more than 30 years. It is…”
Get more information

Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome by Shulman, L N, Frisard, B, Antin, J H, Wheeler, C, Pinkus, G, Magauran, N, Mauch, P, Nobles, E, Mashal, R, Canellos, G

“…A study was undertaken to improve our understanding of the clinicopathologic features and therapeutic outcome for adults with primary Ki-1 anaplastic…”
Get more information

Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion by J P Eder, Jr, J G Supko, T Lynch, M Bryant, E Vosburgh, L N Shulman, G Xu, D W Kufe

“…The camptothecins are a class of potent cytotoxic anticancer agents that interact with the nuclear enzyme topoisomerase I to produce lethal DNA strand…”
Get full text

Difficulties in implementing an organized screening program for breast cancer in Brazil with emphasis on diagnostic methods by Silva, T B, Mauad, E C, Carvalho, A L, Jacobs, L A, Shulman, L N

“…Breast cancer is the most common type of cancer among women, and the leading cause of cancer deaths worldwide. Among early detection methods, screening by…”
Get full text

Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study by Dubey, A, Recht, A, Come, S E, Gelman, R S, Silver, B, Harris, J R, Shulman, L N

“…The optimal sequencing of chemotherapy (CT) and radiotherapy (RT) for patients with early-stage breast cancer treated with breast-conserving therapy is…”
Get more information